Dose-Finding Study of Once-Daily Indinavir/Ritonavir Plus Zidovudine and Lamivudine in HIV-Infected Patients

BACKGROUND:Strategies for treatment of HIV need to be considered in terms of combining potency, safety, and convenience of dosage. However, regimens including once-daily protease inhibitors are not yet available. We have performed a pilot study to determine an indinavir/ritonavir (IND/RTV) regimen f...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of acquired immune deficiency syndromes (1999) 2000-11, Vol.25 (3), p.229-235
Hauptverfasser:	Mallolas, Josep, Blanco, José L, Sarasa, María, Giner, Vicenç, Martinez, Esteban, Garcia-Viejo, Miguel A, Arnaiz, Joan A, Cruceta, Anna, Soy, Dolors, Tuset, Montse, Soriano, Alex, Codina, Carles, Pumarola, Tomás, Carné, Xavier, Gatell, Josep M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antibiotics. Antiinfectious agents. Antiparasitic agents antiretroviral therapy Antiviral agents Biological and medical sciences CD4 Lymphocyte Count Drug therapy Drug Therapy, Combination Experimental viral diseases and models Fundamental and applied biological sciences. Psychology HIV HIV Infections - drug therapy HIV Protease Inhibitors - administration & dosage Human immunodeficiency virus Humans Indinavir - administration & dosage Infectious diseases Lamivudine - administration & dosage Male Medical sciences Microbiology Middle Aged Pharmacology Pharmacology. Drug treatments Pilot Projects Plasma Reverse Transcriptase Inhibitors - administration & dosage Ritonavir - administration & dosage Ritonavir - adverse effects Viral diseases Viral Load Zidovudine - administration & dosage
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	BACKGROUND:Strategies for treatment of HIV need to be considered in terms of combining potency, safety, and convenience of dosage. However, regimens including once-daily protease inhibitors are not yet available. We have performed a pilot study to determine an indinavir/ritonavir (IND/RTV) regimen for once-daily dosing, by monitoring plasma levels. METHODS:Antiretroviral-naive HIV-infected adults were eligible. Therapy was zidovudine/lamivudine 1 pill twice daily plus IND/RIT (liquid formulation) 800/100 mg twice daily with food. At 4-week intervals, plasma levels were measured and dosage of IND/RIT switched to 1000/100 mg daily and then 800/200 mg daily. If 12-hour minimum concentrations (Cmin12h) of IND were too low (
ISSN:	1525-4135 1944-7884
DOI:	10.1097/00042560-200011010-00004